Primary adrenal angiosarcoma is a rare, malignant, vascular neoplasm. These neoplasms typically arise in middle age (median age of 60 years) and are more common in males (65%) than in females. Although rare, these neoplasms are aggressive with a propensity for local recurrence and metastasis and a median survival of 18 months. We present 2 cases of primary adrenal angiosarcoma with synchronous, ipsilateral adrenocortical adenomas. We review the cases of adrenal angiosarcoma reported since 1988 and discuss their clinical and histopathologic characteristics.
Lepoutre-LusseyCRousseauAAl GhuzlanA, et al.Primary adrenal angiosarcoma and functioning adrenocortical adenoma: an exceptional combined tumor. Eur J Endocrinol. 2012;166(1):131-135. doi:10.1530/EJE-11-0791
6.
HendrySForrestC. Epithelioid angiosarcoma arising in an adrenal cortical adenoma: a case report and review of the literature. Int J Surg Pathol. 2014;22(8):744-748. doi:10.1177/1066896914532541
7.
HayashiTGucerHMeteO. A mimic of sarcomatoid adrenal cortical carcinoma: epithelioid angiosarcoma occurring in adrenal cortical adenoma. Endocr Pathol. 2014;25(4):404-409. doi:10.1007/s12022-014-9330-y
8.
TakizawaKKohashiKNegishiT,et al.A exceptional collision tumor of primary adrenal angiosarcoma and non-functioning adrenocortical adenoma. Pathol Res Pract. 2017;213(6):702-705. doi:10.1016/j.prp.2017.04.017
9.
NohJJChoiSHHwangHKKangCMLeeWJ. Adrenal cavernous hemangioma: a case report with review of the literature. J Pancreas. 2014;15(3):254-257. doi:10.6092/1590-8577/2402
10.
ForestiMParmiggianiA. Adrenal adenoma-hemangioma collision tumor: description of two cases. J Radiol Case Rep. 2019;13(6):1-12. doi:10.3941/jrcr.v13i6.3691
11.
EusebiVCarcangiuMLDinaRRosaiJ. Keratin-positive epithelioid angiosarcoma of thyroid. A report of four cases. Am J Surg Pathol. 1990;14(8):737-747. doi:10.1097/00000478-199008000-00004
12.
PapottiMArrondiniMTavaglioneVVeltriAVolanteM. Diagnostic controversies in vascular proliferations of the thyroid gland. Endocr Pathol. 2008;19(3):175-183. doi:10.1007/s12022-008-9039-x
13.
PetronellaPScorzelliMLuiseR, et al.Primary thyroid angiosarcoma: an unusual localization. World J Surg Oncol. 2012;10:73. doi:10.1186/1477-7819-10-73
KefeliMMeteO. An unusual malignant thyroid nodule: coexistence of epithelioid angiosarcoma and follicular variant papillary thyroid carcinoma. Endocr Pathol. 2014;25(3):350-352. doi:10.1007/s12022-013-9243-1
16.
IlvesmäkiVKahriAIMiettinenPJ, et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab. 1993;77(3):852-858. doi:10.1210/jcem.77.3.8370710
17.
GiordanoTJThomasDGKuickR, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003;162(2):521-531. doi:10.1016/S0002-9440(10)63846-1
18.
TissierFCavardCGroussinL, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65(17):7622-7627. doi:10.1158/0008-5472.CAN-05-0593
19.
AlmeidaMQAzevedoMFXekoukiP, et al. Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. J Clin Endocrinol Metab. 2012;97(4):E687-E693. doi:10.1210/jc.2011-3000
20.
MentzelTSchildhausHUPalmedoG, et al. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol. 2012;25(1):75-85. doi:10.1038/modpathol.2011.134
21.
CornejoKMDengAWuH, et al. The utility of MYC and FLT4 in the diagnosis and treatment of postradiation atypical vascular lesion and angiosarcoma of the breast. Hum Pathol. 2015;46(6):868-875. doi:10.1016/j.humpath.2015.02.014
22.
AntonescuCRYoshidaAGuoT, et al. KDR Activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69(18):7175-7179. doi:10.1158/0008-5472.CAN-09-2068
23.
BehjatiSTarpeyPSSheldonH, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. 2014;46(4):376-379. doi:10.1038/ng.2921
24.
KunzeKSpiekerTGamerdingerU, et al. A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells. Cancer Res. 2014;74(21):6173-6183. doi:10.1158/0008-5472.CAN-14-1162
25.
MuraliRChandramohanRMöllerI, et al. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget. 2015;6(34):36041-36052. doi:10.18632/oncotarget.5936
26.
HuangSCZhangLSungYS, et al. Recurrent CIC gene abnormalities in angiosarcomas: a molecular study of 120 cases with concurrent investigation of PLCG1, KDR, MYC, and FLT4 gene alterations. Am J Surg Pathol. 2016;40(5):645-655. doi:10.1097/PAS.0000000000000582
27.
CornejoKMHutchinsonLCyrMS,et al.MYC Analysis by fluorescent in situ hybridization and immunohistochemistry in primary adrenal angiosarcoma (PAA): a series of four cases. Endocr Pathol. 2015;26(4):334-341. doi:10.1007/s12022-015-9385-4
28.
BallingerMLGoodeDLRay-CoquardI, et al. International sarcoma kindred study. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016;17(9):1261-1271. doi:10.1016/S1470-2045(16)30147-4
29.
ZhangCXuGLiuZ, et al. Epidemiology, tumor characteristics and survival in patients with angiosarcoma in the United States: a population-based study of 4537 cases. Jpn J Clin Oncol. 2019;49(12):1092-1099. doi:10.1093/jjco/hyz113
30.
BuehlerDRiceSRMoodyJS, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014;37(5):473-479. doi:10.1097/COC.0b013e31827e4e7b
31.
FlorouVWilkyBA. Current and future directions for angiosarcoma therapy. Curr Treat Options Oncol. 2018;19(3):14. doi:10.1007/s11864-018-0531-3
32.
BottiGScognamiglioGMarraL, et al.Programmed death ligand 1 (PD-L1) expression in primary angiosarcoma. J Cancer. 2017;8(16):3166-3172. doi:10.7150/jca.19060
33.
SindhuSGimberLHCranmerLMcBrideAKraftAS. Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. J Immunother Cancer. 2017;5(1):58. doi:10.1186/s40425-017-0263-0
34.
ZhengYWZhangXWZhangJL, et al. Primary hepatic angiosarcoma and potential treatment options. J Gastroenterol Hepatol. 2014;29(5):906-911. doi:10.1111/jgh.12506
35.
LiRLiMZhangLF, et al. Clinical characteristics and prognostic factors of primary splenic angiosarcoma: a retrospective clinical analysis from China. Cell Physiol Biochem. 2018;49(5):1959-1969. doi:10.1159/000493656
36.
ZhangCHuangCZhangX, et al. Clinical characteristics associated with primary cardiac angiosarcoma outcomes: a surveillance, epidemiology and end result analysis. Eur J Med Res. 2019;24(1):29. doi:10.1186/s40001-019-0389-2
37.
WangBChenLJWangXY. A clinical model of bone angiosarcoma patients: a population-based analysis of epidemiology, prognosis, and treatment. Orthop Surg.2020;12(6):1652-1662. doi:10.1111/os.12803
38.
PalmeriniEMakiRGStaalsEL, et al. Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions. Am J Clin Oncol. 2014;37(6):528-534. doi:10.1097/COC.0b013e31827defa1
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
